References
- Radbruch L, Grond S, Zech D, et al. High-dose oral morphine in cancer pain management: a report of twelve cases. J Clin Anesth 1996;8:144-50
- Bercovitch M, Adunsky A. Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it? Cancer 2004;101:1473-7
- Bercovitch M, Waller A, Adunsky A. High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy. Cancer 1999;86:871-7
- Mercadante S, Ferrera P, David F, et al. The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Med 2011;28:242-4
- Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliat Med 2011;25:471-7
- Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-92
- Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2007;24:297-305
- Sathyan G, Xu E, Thipphawong J, et al. Pharmacokinetic profile of a 24 hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol 2007;7:2
- Hanna M, Thipphawong J. A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 2008;7:17
- Hanna M, Tuca A, Thipphawong J. An open-label, 1 year extension study of the long-term safety and efficacy of once-daily OROS hydromorphone in patients with chronic cancer pain. BMC Palliat Care 2009;8:14
- Wallace M, Moulin DE, Rauck RL, et al. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manage 2009;5:97-105
- Bercovitch M, Adunsky A. High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharm 2006;20:33-9
- Ferrarese F, Becchimanzi G, Bernardo M, et al. Pain treatment with high dose, controlled release oxycodone: an Italian perspective. Ther Clin Risk Manage 2008;4:665-71
- Viganó A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer 1998;83:1244-50
- Mercadante S, Arcuri E. Pharmacological management of cancer pain in the elderly. Drugs Aging 2007;24:761-76
- Moulin DE, Richarz U, Wallace M, et al. Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies. J Pain Palliat Care Pharmacother 2010;24:200-12
- Mercadante S, Villari P, Ferrera P, et al. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005;23:5229-34
- Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006;14:56-64
- Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23:355-68